Melanie J. Maslow
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Melanie J. Maslow has a total of 1 co-authors. Here are the top co-authors by number of shared publications:
Irene S. Kourbeti
New York University School of Medicine
1 shared publication
Latest Publications
- 1 June 2000
- Published by Springer Nature in Current Infectious Disease Reports
- Vol. 2 (3) , 193-200
Nontuberculous mycobacterial infections of the lung
There is an increasing appreciation for the role of nontuberculous mycobacteria (NTM) as pathogens causing pulmonary disease, disseminated disease, or both in immunocompetent and immunocompromised individuals. Species previously considered nonpathogenic have been shown to cause pulmonary infection. The majority of immunocompetent patients with NTM pulmonary infection have underlying lung disease. New diagnostic techniques such as gene probes, gas-liquid and high-pressure chromatography, and polymerase chain reaction offer significant advantages in the rapid identification of NTM species. Some of these techniques allow identification of mycobacteria directly from clinical specimens. The fluoroquinolones, rifabutin, and newer macrolides offer advances in the treatment of infections that are caused by NTM and are resistant to the traditional antimycobacterial drugs.
- 1 June 2000
- Published by Springer Nature in Current Infectious Disease Reports
- Vol. 2 (3) , 193-200
Nontuberculous mycobacterial infections of the lung
There is an increasing appreciation for the role of nontuberculous mycobacteria (NTM) as pathogens causing pulmonary disease, disseminated disease, or both in immunocompetent and immunocompromised individuals. Species previously considered nonpathogenic have been shown to cause pulmonary infection. The majority of immunocompetent patients with NTM pulmonary infection have underlying lung disease. New diagnostic techniques such as gene probes, gas-liquid and high-pressure chromatography, and polymerase chain reaction offer significant advantages in the rapid identification of NTM species. Some of these techniques allow identification of mycobacteria directly from clinical specimens. The fluoroquinolones, rifabutin, and newer macrolides offer advances in the treatment of infections that are caused by NTM and are resistant to the traditional antimycobacterial drugs.